DGIdb - ISOPROTERENOL Drug Record

ISOPROTERENOL chembl:CHEMBL434 Approved

Alternate Names:

ISOPROTERENOL
NSC-9975
ISOPROTERENOL DL-FORM
NSC-33791
ISOPRENALINE
A-21
3,4-DIHYDROXY-ALPHA-[(ISOPROPYLAMINO)METHYL]BENZYL ALCOHOL
(+-)-ISOPRENALINE
1-(3,4-DIHYDROXYPHENYL)-2-ISOPROPYLAMINOETHANOL
N-ISOPROPYL-BETA-DIHYDROXYPHENYL-BETA-HYDROXYETHYLAMINE
N-ISOPROPYLNORADRENALINE
Α-(ISOPROPYLAMINOMETHYL)PROTOCATECHUYL ALCOHOL
(±)-ISOPROTERENOL
1-(3,4-DIHYDROXYPHENYL)-2-(ISOPROPYLAMINO)ETHANOL
ISOPRENALINUM
(±)-ISOPRENALINE
ISOPROPYL NORADRENALINE
N-ISOPROPYL-Β-DIHYDROXYPHENYL-Β-HYDROXYETHYLAMINE
ISOPRENALINA
N-ISOPROPYLNOREPINEPHRINE
(+-)-ISOPROTERENOL
ALPHA-(ISOPROPYLAMINOMETHYL)PROTOCATECHUYL ALCOHOL
chemidplus:7683-59-2
pubchem.compound:3779
chembl:CHEMBL434
drugbank:01064

Drug Info:

Drug Class	bronchodilator agents
Drug Class	cardiotonic agents
Year of Approval	approved before 1982
FDA Approval	Approved before 1982
Drug Class	small molecule
Drug Indications	Cardiotonic Agents
Drug Indications	Bronchodilator Agents

(4 More Sources)

Publications:

Levi et al., 1993, Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions., Proc. Natl. Acad. Sci. U.S.A.
Ahlquist, 1976, Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor., Am. Heart J.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Jurgens et al., 2005, Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity., J. Pharmacol. Exp. Ther.
Kobayashi et al., 2005, Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK., Cell. Signal.
Sato et al., 2004, Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger., J. Mol. Cell. Cardiol.
McCrink KA et al., 2016, β<sub>1</sub>-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes., Pharmacogenomics
Dishy V et al., 2001, The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization., N Engl J Med
Angers et al., 2001, Biochemical and biophysical demonstration of GPCR oligomerization in mammalian cells., Life Sci.
Ding et al., 2000, Modulation of porcine adipocyte beta-adrenergic receptors by a beta-adrenergic agonist., J. Anim. Sci.
Skoumbourdis AP et al., 2009, Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors., Bioorg Med Chem Lett
MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
Jones et al., 2003, Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer., BMC Pharmacol.
Odley et al., 2004, Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling., Proc. Natl. Acad. Sci. U.S.A.
Uezono et al., 2004, Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the Xenopus oocyte expression system., Am. J. Physiol., Cell Physiol.
Teixeira et al., 2004, Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum., J. Pharmacol. Exp. Ther.
Abraham et al., 2003, Pharmacological and biochemical characterization of the beta-adrenergic signal transduction pathway in different segments of the respiratory tract., Biochem. Pharmacol.
Lemmens et al., 2004, Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase., Circulation
Morimoto et al., 2001, Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells., J. Lipid Res.
Borger et al., 1998, Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype., Am. J. Respir. Cell Mol. Biol.
Perrino et al., 2005, Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression., J. Am. Coll. Cardiol.
Udelsman et al., 1994, Adrenergic regulation of adrenal and aortic heat shock protein., Surgery
Hupfeld et al., 2003, Beta -Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes., Proc. Natl. Acad. Sci. U.S.A.
Steinlechner et al., 1984, Comparison of the effects of beta-adrenergic agents on pineal serotonin N-acetyltransferase activity and melatonin content in two species of hamsters., J. Pineal Res.
Mendelson et al., 1984, Regulation of aromatase activity of cultured adipose stromal cells by catecholamines and adrenocorticotropin., Mol. Cell. Endocrinol.
Sasikumar et al., 2000, Effect of abana an ayurvedic formulation, on lipid peroxidation in experimental myocardial infarction in rats., Indian J. Exp. Biol.
Matsumoto et al., 2005, Sorcin interacts with sarcoplasmic reticulum Ca(2+)-ATPase and modulates excitation-contraction coupling in the heart., Basic Res. Cardiol.

ISOPROTERENOL LIPE

Interaction Score: 4.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11160373

Sources:
NCI
ISOPROTERENOL AANAT

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6152777

Sources:
NCI
ISOPROTERENOL SRI

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15754088

Sources:
NCI
ISOPROTERENOL IL12B

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ISOPROTERENOL ADRB2

Interaction Score: 0.33

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11586955 14734046 11358333 10784181 19464886 16680159 10722 14656380 15105445 11752352 15151902 14752060 12963495

Sources:
DTC TdgClinicalTrial NCI TEND PharmGKB TTD
ISOPROTERENOL CP

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12557918

Sources:
NCI
ISOPROTERENOL ADRB1

Interaction Score: 0.27

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10722 11752352 15908512 16038799 14734046 27643874

Sources:
TdgClinicalTrial TEND PharmGKB TTD
ISOPROTERENOL NRG1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14732742

Sources:
NCI
ISOPROTERENOL GFAP

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8381971

Sources:
NCI
ISOPROTERENOL MAPK10

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12509508

Sources:
NCI
ISOPROTERENOL HSPA4

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8047983

Sources:
NCI
ISOPROTERENOL CYP19A1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6205918

Sources:
NCI
ISOPROTERENOL CSF2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9730867

Sources:
NCI
ISOPROTERENOL ADRA1D

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ISOPROTERENOL PIK3CG

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15936620

Sources:
NCI
ISOPROTERENOL ADRA2B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ISOPROTERENOL ADRA1B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ISOPROTERENOL ADRA2C

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ISOPROTERENOL ADRA2A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ISOPROTERENOL ADRA1A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ISOPROTERENOL TSHR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL HIF1A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOPROTERENOL CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: ISOPROTERENOL
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval approved before 1982

Drug Class cardiotonic agents

Drug Class bronchodilator agents

Publications:
TdgClinicalTrial: ISOPROTERENOL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Bronchodilator Agents

Drug Indications Cardiotonic Agents

Drug Class small molecule

Publications:

NCI: ISOPROTERENOL

Version: 14-September-2017

Alternate Names:

C29133 NCI drug code

Drug Info:

Publications:

Lemmens et al., 2004, Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase., Circulation

Morimoto et al., 2001, Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells., J. Lipid Res.

Perrino et al., 2005, Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression., J. Am. Coll. Cardiol.

DTC: ISOPROTERENOL

Version: 02-September-2020

Alternate Names:

CHEMBL434 ChEMBL Drug ID

Drug Info:

Publications:

Skoumbourdis AP et al., 2009, Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors., Bioorg Med Chem Lett

MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

PharmGKB: isoproterenol

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

McCrink KA et al., 2016, β<sub>1</sub>-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes., Pharmacogenomics

Dishy V et al., 2001, The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization., N Engl J Med

DTC: ISOPRENALINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1160723 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Isoproterenol
- Version: 2020.06.01
Alternate Names:

D0I8FI TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL434
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

ISOPROTERENOL Drug Record

ISOPROTERENOL chembl:CHEMBL434 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11160373

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6152777

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15754088

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 11586955 14734046 11358333 10784181 19464886 16680159 10722 14656380 15105445 11752352 15151902 14752060 12963495

Sources: DTC TdgClinicalTrial NCI TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12557918

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10722 11752352 15908512 16038799 14734046 27643874

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14732742

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8381971

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12509508

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8047983

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6205918

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9730867

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15936620

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
11160373

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6152777

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15754088

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11586955 14734046 11358333 10784181 19464886 16680159 10722 14656380 15105445 11752352 15151902 14752060 12963495

Sources:
DTC TdgClinicalTrial NCI TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
12557918

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10722 11752352 15908512 16038799 14734046 27643874

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
14732742

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8381971

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12509508

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8047983

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6205918

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9730867

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15936620

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC